Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Liz Highleyman
The hepatitis C virus polymerase inhibitor sofosbuvir produces high rates of sustained virological response for genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data from the ELECTRON trial presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Liz Highleyman
A 12-week once-daily regimen of 2 direct-acting hepatitis C drugs -- sofosbuvir (formerly GS-7977) and daclatasvir (formerly BMS-790052) -- produced sustained virological response rates for treatment-naive patients in the 90% to 100% range, and appeared effective regardless of HCV subtype, IL28B pattern, or use of ribavirin, according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston. The developers are not planning further studies of this combination, however, leaving its fate uncertain. 
AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
Tenofovir (Viread) continues to be safe and highly effective for treating chronic hepatitis B through 8 years of follow-up, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this week in Boston. Another study showed minimal bone loss among tenofovir-treated patients using the FRAX method. 
AASLD 2012: Daclatasvir + Asunaprevir + BMS-791325 Cures Hard-to-treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Keith Alcorn
Twelve weeks of treatment with a 3-drug combination of new hepatitis C direct-acting antivirals that included neither pegylated interferon nor ribavirin led to sustained virological response 12 weeks after completion of treatment (SVR12) in up to 94% of previously untreated patients with hepatitis C genotype 1 in a preliminary Phase 2 trial with 16 patients, Gregory Everson from the University of Colorado reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: Abbott Interferon-free Combination 'Promising' in Harder-to-treat People with Hep C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 13 November 2012 00:00
- Written by Keith Alcorn
Over 79% of previously untreated and null-responder patients with genotype 1a hepatitis C achieved a sustained virological response 12 weeks after completing treatment with an interferon-free combination of 2 or 3 direct-acting antiviral agents developed by Abbott (ABT-450, ABT-267, and/or ABT-333), investigators reported at the American Association for the Stu
dy of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
More Articles...
- Coverage of the 2012 AASLD Liver Meeting
- AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Bacterial Translocation Linked to Severe Liver Disease among HIV/HCV Coinfected People
Web Design and Development by